Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation compared with mice with an intact FGFR2 gene. In addition, the combined ...

individuals with fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement. The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics ...

One finding in particular caught Ding’s attention. Hypomethylation on fibroblast growth factor receptor 2 (FGFR2), a receptor tyrosine kinase (RTK) oncogene, increased transcript and protein abundance ...

FGFR2 fusion occurs in 10-15% of IHCC patients ... (“IHCC”) patients with fibroblast growth factor receptor (“FGFR”)2 fusion/rearrangement. The study is a single-arm, multi-center, open ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

DelveInsight’s “BALVERSA Market Size, Forecast, and Market Insight Report” highlights the details around BALVERSA, a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor.